| Medication                                      | Number of patients |
|------------------------------------------------|--------------------|
| No Medication                                  | 52                 |
| **Individual Therapies**                       |                    |
| Anti-IL-6                                      | 3                  |
| Remdesivir                                     | 6                  |
| Leronlimab                                     | 6                  |
| Hydroxychloroquine                             | 15                 |
| **Combination Therapies**                      |                    |
| Anti-IL-6 and Remdesivir                       | 1                  |
| Anti-IL-6 and Leronlimab                       | 3                  |
| Anti-IL-6 and Hydroxychloroquine               | 14                 |
| Remdesivir and Leronlimab                      | 1                  |
| Remdesivir and Hydroxychloroquine              | 2                  |
| Leronlimab and Hydroxychloroquine              | 2                  |
| Anti-IL-6 and Leronlimab and Hydroxychloroquine| 1                  |
| Anti-IL-6 and Remdesivir and Hydroxychloroquine| 5                  |
| Anti-IL-6 and Remdesivir and Leronlimab and Hydroxychloroquine | 1 |

*Anti-IL 6 therapies include tocilizumab and sarilumab. Patients in these groups received only one type.*
Supplemental Table 2: Interventions administered open label or via trial enrollment. Those enrolled in clinical trial received either the listed medication or placebo in a blinded fashion.

| Medication          | Total | % in Trial | % Open Label |
|---------------------|-------|------------|--------------|
| Hydroxychloroquine  | 40    | 0%         | 100%         |
| Leronlimab          | 14    | 7%         | 93%          |
| Remdesivir (or placebo) | 16 | 88%       | 22%          |
| Sarilumab (or placebo) | 9 | 100%       | 0%           |
| Tocilizumab         | 19    | 21%        | 79%          |

Supplemental Table 3: Reported Indication for Therapeutic Dose Anticoagulation

| Anticoagulation Indication                      | N  |
|------------------------------------------------|----|
| Acute Coronary Syndrome                        | 1  |
| Atrial Fibrillation                            | 6  |
| ECMO                                           | 1  |
| Empiric for <24 hours                          | 1  |
| Frequent dialysis line clotting                | 2  |
| Ischemic toe                                   | 1  |
| LV Thrombus                                    | 1  |
| New in-hospital VTE                            | 6  |
| Past Medical History (includes prior VTE)      | 7  |
Supplemental Figure 1: Combined COVID-19 admissions by date for both Ronald Reagan UCLA and Santa Monica UCLA. Of note, one admission from December and one from February, both of whom contracted COVID-19 during hospitalization were omitted from this histogram for ease of interpretation.